Pfanstiehl, Inc.
David Schaad is an experienced professional in the field of chemistry, currently serving as the Director of Research and Development at Pfanstiehl, Inc. since 2014, where responsibilities include overseeing process chemistry, kilo lab operations, and managing R&D projects, alongside conducting intellectual property assessments and initiating quarterly product launches. Prior experience includes a managerial role at Ferro Corporation, where oversight of API chemical development and manufacturing was a focus, and positions at Albany Molecular Research, Monsanto Company, and The NutraSweet Company, each contributing to extensive expertise in project management and process optimization. David Schaad holds a Ph.D. in Chemistry from the University of Colorado Boulder and a B.S. in Chemistry from the University of Wisconsin-Madison.
This person is not in any teams
Pfanstiehl, Inc.
1 followers
Founded in 1919 by Carl A. Pfanstiehl, our company specializes in isolation, purification, custom synthesis and scale-up development of cGMP, high purity and low endotoxin (HPLE) Injectable Formulation Components, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API’s), in gram to multi-ton commercial quantities. Tried and true parenteral excipients include trehalose, sucrose, mannitol, maltose, sorbitol, and hydroxypropyl betacyclodextrin. Upstream, high purity media components include animal component free galactose, mannose, and L-arginine. At Pfanstiehl we pride ourselves on being customer focused and are amenable to producing cGMP components on a custom basis to solve formulation challenges for our clients.